natgillin/translations-raw huggingface dataset:
The pharmaceutical formulation of claim 1-6, wherein the pharmaceutical formulation is a dry powder formulation. 
Farmaceutska formulacija prema zahtjevu 1-6, naznačena time da farmaceutska formulacija je suha praškasta formulacija.
The pharmaceutical formulation of claim 11 or 12, wherein the calcium salt is selected from the group consisting of calcium chloride, calcium carbonate, calcium acetate, calcium phosphate, calcium alginate, calcium stearate, calcium sorbate, calcium sulfate, calcium gluconate, calcium lactate and calcium citrate, optionally, wherein the calcium salt is calcium lactate, calcium citrate, calcium sulfate, or calcium chloride. 
Farmaceutska formulacija prema zahtjevu 11 ili 12, naznačena time da kalcijeva sol je odabrana iz skupine koja sadrži kalcijev klorid, kalcijev karbonat, kalcijev acetat, kalcijev fosfat, kalcijev alginat, kalcijev stearat, kalcijev sorbat, kalcijev sulfat, kalcijev glukonat, kalcijev laktat i kalcijev citrat, pri čemu proizvoljno kalcijeva sol je kalcijev laktat, kalcijev citrat, kalcijev sulfat ili kalcijev klorid.
The pharmaceutical formulation of any one of claims 11-13, wherein the sodium salt is selected from the group consisting of sodium chloride, sodium acetate, sodium bicarbonate, sodium carbonate, sodium sulfate, sodium stearate, sodium ascorbate, sodium benzoate, sodium biphosphate, sodium phosphate, sodium bisulfite, sodium citrate, sodium borate, sodium gluconate, sodium metasilicate, and sodium lactate, optionally, wherein the sodium salt is sodium chloride, or wherein the sodium salt is sodium lactate, sodium citrate, or sodium sulfate. 
Farmaceutska formulacija prema bilo kojem od zahtjeva 11-13, naznačena time da natrijeva sol je odabrana iz skupine koja sadrži natrijev klorid, natrijev acetat, natrijev bikarbonat, natrijev karbonat, natrijev sulfat, natrijev stearat, natrijev askorbat, natrijev benzoat, natrijev bifosfat, natrijev fosfat, natrijev bisulfit, natrijev citrat, natrijev borat, natrijev glukonat, natrijev metasilikat, te natrijev laktat, pri čemu proizvoljno natrijeva sol je natrijev klorid, ili pri čemu natrijeva sol je natrijev laktat, natrijev citrat, ili natrijev sulfat.
An effective amount of the pharmaceutical formulation of any one of claims 1-16 for use in treating a pulmonary disease in an individual having a pulmonary disease, exhibiting symptoms of a pulmonary disease, or susceptible to a pulmonary disease. 
Učinkovita količina farmaceutske formulacije prema bilo kojem od zahtjeva 1-16 naznačena time da je za uporabu za liječenje plućne bolesti kod pojedinca koji ima plućnu bolest, pokazuje simptome plućne bolesti, ili je podložan dobivanju plućne bolesti.
An effective amount of the pharmaceutical formulation of any one of claims 1-16 for use in treating an acute exacerbation of a pulmonary disease in an individual having an acute exacerbation of a pulmonary disease, exhibiting symptoms of an acute exacerbation of a pulmonary disease, or susceptible to an acute exacerbation of a pulmonary disease,. 
Učinkovita količina farmaceutske formulacije prema bilo kojem od zahtjeva 1-16 naznačena time da je za uporabu kod liječenja akutne egzacerbacije plućne bolesti kod pojedinca koji ima akutnu egzacerbaciju plućne bolesti, pokazuje simptome akutne egzacerbacije plućne bolesti, ili je podložan dobivanju akutne egzacerbacije plućne bolesti.
The pharmaceutical formulation of claims 20 or 21, wherein the pulmonary disease is asthma, airway hyperresponsiveness, allergic rhinitis, seasonal allergic allergy, brochiectasis, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, or cystic fibrosis. 
Farmaceutska formulacija prema zahtjevima 20 ili 21, naznačena time da plućna bolest je astma, preosjetljivost dišnih putova, alergijski rinitis, sezonska alergija, bronhiektazija, kronični bronhitis, emfizem, kronična opstruktivna plućna bolest ili cistična fibroza.
Process of activation of a landfill of municipal solid waste (MSW) dried by means of an aerobic digestion to a humidity content lower than 20% by weight, placed on an impermeable containing sheet (T) and covered at the top with a layer of clay with low permeability to gases and to liquids, characterised by the step of feeding of water into the landfill until humidity contents of around 30-60% by weight are reached to trigger a process of anaerobic digestion with production of biogas comprising 40-50% methane. 
Postupak aktivacije odlagališta komunalnog krutog otpada (MSW), čiji je sadržaj vlage pomoću aerobne obrade spušten ispod 20% težinski, koji je položen na vodo-nepropusnu podlogu (T) i prekriven po vrhu slojem gline niske propusnosti na plinove i tekućine, naznačen time da se dovođenjem vode u odlagalište podigne sadržaj vlage na 30-60% težinski, i time izazove anaerobno razlaganje i razvijanje bioplina koji sadrži 40-50%metana.
Process according to claim 1 or 2, characterised by the further step of recycling the landfill percolate, after possible treatment of the same, for use in addition to or in place of the water for activation of the MSW or compressed bales. 
Postupak prema 1. ili 2. zahtjevu, naznačen time da se procjedne vode odlagališta, nakon eventualne obrade, recikliraju i koriste kao dodatak ili umjesto vode za aktivaciju MSW-a ili komprimiranih bala.
A method of evaluating the composition of a cell culture, said method comprising: 
Postupak procjenjivanja sastava stanične kulture, naznačen time, da navedeni postupak sadrži:
obtaining a plurality of cells from a cell culture; 
dobivanje mnoštva stanica iz stanične kulture;
determining the average expression level of a fibroblast marker in the plurality of cells wherein said fibroblast marker is microfibrillar associated protein 5 (MFAP5); and 
utvrđivanje prosječne razine ekspresije markera fibroblasta u mnoštvu stanica pri čemu je navedeni marker fibroblasta mikrofibrilarni udruženi protein 5 (MFAP5); te
determining the composition of the culture based on the average expression level of microfibrillar associated protein 5 (MFAP5); wherein the average expression level of MFAP5 below a predetermined threshold indicates that the cell culture comprises chondrocytes. 
utvrđivanje sastava kulture na temelju prosječne razine ekspresije mikrofibrilarnog udruženog proteina 5 (MFAP5); pri čemu prosječna razina ekspresije MFAP5 ispod prethodno utvrđenog praga naznačuje da stanična kultura sadrži kondrocite.
The method of claim 1, wherein the fibroblast marker MFAP5 is such that its normalized expression levels are lower in passaged chondrocytes than in dermal fibroblasts or synoviocytes. 
Postupak prema zahtjevu 1, naznačen time, da je marker fibroblasta MFAP5 takav da su njegove normalizirane razine ekspresije niže kod prijelaznih kondrocita nego kod dermalnih fibroblasta ili sinoviocita.
The method of claim 1, further comprising determining the average expression level of a chondrocyte marker in the plurality of cells; and, in step c), determining the composition of the culture based on the average expression level of the chondrocyte marker and the average expression level of the chondrocyte and fibroblast marker MFAP5. 
Postupak prema zahtjevu 1, naznačen time, da nadalje sadrži utvrđivanje prosječne razine ekspresije kondrocitnog markera u mnoštvu stanica; te u koraku c), utvrđivanje sastava kulture na temelju prosječne razine ekspresije kondrocitnog markera i prosječne razine ekspresije kondrocitnog markera i markera fibroblasta MFAP5.
The method of claim 3, wherein the expression levels of the fibroblast marker MFAP5 and chondrocyte markers are determined at the RNA level. 
Postupak prema zahtjevu 3, naznačen time, da su razine ekspresije markera fibroblasta MFAP5 i kondrocitnih markera, utvrđene na razini RNK.
The method of claim 18, wherein the expression levels are determined using comparative CT PCR method. 
Postupak prema zahtjevu 18, naznačen time, da su razine ekspresije utvrđene korištenjem komparativnog CT PCR postupka.
The method of claim 20, wherein said ratio indicates that the cell culture contains at least 50% chondrocytes. 
Postupak prema zahtjevu 20, naznačen time, da navedeni omjer naznačuje da stanična kultura sadrži najmanje 50% kondrocita.
The method of claim 22, wherein said molar ratio indicates that the cell culture contains at least 50% chondrocytes. 
Postupak prema zahtjevu 22, naznačen time, da navedeni molarni omjer naznačuje da stanična kultura sadrži najmanje 50% kondrocita.
isolating cells from a cartilage biopsy obtained from a mammal; 
izoliranje stanica iz biopsije hrskavice uzetih od sisavca;
culturing cells isolated in step a) in a cell culture; 
kultiviranje stanica izoliranih u koraku a) u staničnoj kulturi;
determining the composition of the culture based on the expression levels of MFAP5 and HAPLN1. 
utvrđivanje sastava kulture na temelju razine ekspresije MFAP5 i HAPLN1.
The method of claim 16, wherein the expression levels of MFAP5 and HAPLN1 are determined at the RNA level. 
Postupak prema zahtjevu 16, naznačen time, da su razine ekspresije MFAP5 i HAPLN1 utvrđene na razini RNK.
Use of a combination of topical R,R-glycopyrrolate or its physiologically acceptable salts with phosphodiesterase (PDE) 4 inhibitors selected from a group comprising rolipram, roflumilast or their physiologically acceptable salts for the production of a medicament for the treatment of bronchial asthma or chronic obstructive pulmonary disease (COPD). 
Uporaba kombinacije topičkog R,R-glikopirolata ili njegove fiziološki prihvatljive soli s inhibitorima (PDE) 4 fosfodiesteraze odabrane iz skupine koja sadrži rolipram, roflumilast ili njihove fiziološki prihvatljive soli, naznačena time, da je za proizvodnju lijeka za liječenje bronhijalne astme ili kronične opstruktivne bolesti pluća (COPD).
Process according to claim 6, characterized in that the two active substances are available in an appropriate particle size dispersion when inhaled. 
Postupak u skladu s patentnim zahtjevom 6, naznačen time, da su omogućene dvije djelatne tvari u prikladnoj veličini čestica za raspršivanje kada se inhaliraju.
Process according to claim 6, characterized in that it is an inhalable dry powder 
Postupak u skladu s patentnim zahtjevom 6, naznačen time, da je suhi prašak za inhalaciju.
coupling a compound of formula II or a salt thereof, in which P1 represents a hydrogen atom or a hydroxyl protecting group, with a compound of formula III in which Z represents a leaving group, or the corresponding isocyanate; or 
kondenziranju spoja formule II [image] ili njegove soli, u kojoj P1 predstavlja atom vodika ili zaštitnu skupinu za hidroksil, sa spojem formule III [image] u kojoj Z predstavlja izlaznu skupinu ili odgovarajući izocijanat; ili
The use of a compound according to claim 1 in the manufacture of a medicament for the treatment of a kinase-mediated condition in a mammal. 
Upotreba spoja u skladu s patentnim zahtjevom 1, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje stanja posredovanog kinazama kod sisavca.
The use according to claim 9, wherein said kinase-mediated condition is inflammatory disease, autoimmune disease, destructive bone disorder, proliferative disorder, infectious disease, viral disease, or neurodegenerative disease. 
Upotreba u skladu s patentnim zahtjevom 9, naznačena time što je navedeno stanje posredovano kinazama upalna bolest, autoimuna bolest, destruktivni poremećaj kostiju, proliferativni poremećaj, zarazna bolest, virusna bolest, ili neurodegenerativna bolest.
The process of claim 2, wherein said compound of formula (II) has been prepared by the method comprising: 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što se navedeni spoj formule (II) dobiva postupkom koji se sastoji u:
Process for the preparation of a compound of formula (I) wherein R' is hydrogen and R" is 4-chloro-phenyl, which comprises reacting a compound of formula (II), in cis form or as a cis/trans mixture, wherein 
Postupak za pripremu spoja formule (I) [image] naznačen time, da R' jest vodik, a R'' jest 4-klor-fenil, koji postupak obuhvaća reagiranje spoja formule (II) u cis obliku ili kao cis/trans smjesi, [image] u čemu
R' and R" are as defined above, and 
R' i R'' jesu kao što su definirani gore, a
Process as claimed in the claims from 1 to 3, wherein the reaction is performed at a temperature below +15°C. 
Postupak prema patentnim zahtjevima 1 do 3, naznačen time, da se reakcija izvodi pri temperaturi ispod +15oC.
Process as claimed in claims 7 or 8 for the preparation of atovaquone. 
Postupak prema patentnom zahtjevu 7 ili 8, naznačen time, da jest za pripremu atovakvona.
The IL-18BP according to claim 1, wherein the moiety is a polyethylene glycol (PEG) moiety. 
IL-18BP prema zahtjevu 1, naznačen time da navedena skupina je polietilen glikol (PEG) skupina.
Process for production of an IL-18BP according to claim 1 or 2 comprising the step of isolating the IL-18BP from the cell culture supernatant of a host cell comprising a nucleic acid coding for an IL-18BP according to claims 1 or 2. 
Postupak dobivanja IL-18BP prema zahtjevu 1 ili 2 naznačen time da sadrži korak izoliranja IL-18BP iz supernatantne stanične kulture stanice domaćina koji se sastoji od kodiranja nukleinske kiseline za IL-18BP prema zahtjevima 1 ili 2.
Use according of IL-18 BP according to any one of claims 1 to 3, for the preparation of a medicament for treatment and/or prevention of a disease selected from: tumor metastasis, psoriasis, arthritis, in particular rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, liver injury, atherosclerosis, sepsis, myocardial infarction, traumatic brain injury, allergy, peripheral vascular disease, multiple sclerosis. 
Uporaba IL-18 BP prema bilo kojem od zahtjeva 1 do 3, naznačena time da je za dobivanje lijeka za liječenje i/ili sprečavanje bolesti koje su odabrane od: metastaze tumora, psorijaze, artritisa, naročito reumatoidnog artritisa, upalne bolesti crijeva, Crohnove bolesti, oštećenja jetre, ateroskleroze, sepse, infarkta miokarda, traumatskih oštećenja mozga, alergije, periferne vaskularne bolesti, multiple skleroze.
The use according to claim 8, wherein the interferon is interferon-β. 
Uporaba prema zahtjevu 8, naznačena time da interferon je interferon-β.
Use of an expression vector comprising a nucleic acid coding for an IL-18BP according to claim 1 or 2 for the manufacture of a medicament for the treatment and/or prevention of a disease selected from: tumor metastasis, psoriasis, arthritis, in particular rheumatoid arthritis, inflammatory bowel disease. Crohn's disease, liver injury, atherosclerosis, sepsis, myocardial infarction, traumatic brain injury, allergy, peripheral vascular disease, multiple sclerosis. 
Uporaba ekspresijskog vektora koji sadrži kodiranje nukleinske kiseline za IL-18BP prema zahtjevu 1 ili 2 naznačena time da je za proizvodnju lijeka za liječenje i/ili sprečavanje bolesti koje su odabrane od: metastaze tumora, psorijaze, artritisa, naročito reumatoidnog artritisa, upalne bolesti crijeva, Crohnove bolesti, oštećenja jetre, ateroskleroze, sepse, infarkta miokarda, traumatskih oštećenja mozga, alergije, periferne vaskularne bolesti, multiple skleroze.
Use of a cell that has been genetically modified to produce an IL-18BP according to claim 1 or 2 for the manufacture of a medicament for the treatment and/or prevention of a disease selected from: tumor metastasis, psoriasis, arthritis, rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, liver injury, atherosclerosis, sepsis, myocardial infarction, traumatic brain injury, allergy, peripheral vascular disease, multiple sclerosis. 
Uporaba stanice koja je genetski modificirana za dobivanje IL-18BP prema zahtjevu 1 ili 2 naznačena time da je za proizvodnju lijeka za liječenje i/ili sprečavanje bolesti koje su odabrane od: metastaze tumora, psorijaze, artritisa, reumatoidnog artritisa, upalne bolesti crijeva, Crohnove bolesti, oštećenja jetre, ateroskleroze, sepse, infarkta miokarda, traumatskih oštećenja mozga, alergije, periferne vaskularne bolesti, multiple skleroze.
Spud-pile carnage according to one of the preceding Claims 7 - 12, in which the actuator (19) comprises an accumulator in fluid connection with the first and second pressure chambers (33, 39). 
Kolica za sidreni stup u skladu s jednim od prethodnih patentnih zahtjeva 7 do 12, naznačena time što izvršni uređaj (19) sadržava akumulator koji je preko fluida povezan s prvom tlačnom komorom i s drugom tlačnom komorom (33, 39).
A Cladribine pharmaceutical formulation for use in the treatment of early secondary progressive multiple sclerosis, wherein the formulation is to be orally administered following the sequential steps below: 
Kladribinska farmaceutska formulacija, namijenjena upotrebi u liječenju multiple skleroze, naznačena time što formulaciju treba primijeniti oralno, prema sljedećim koracima, niže:
A maintenance period lasting from 2 months to 4 months, wherein said Cladribine pharmaceutical formulation is to be administered and wherein the total dose of Cladribine reached at the end of the maintenance period (iii) is lower than the total dose of Cladribine reached at the end of the induction period (i); 
period održavanja, koji traje od 2 mjeseca do 4 mjeseca, kada navedenu kladribinsku farmaceutsku formulaciju treba primjenjivati i kada je ukupna doza kladribina postignuta na kraju perioda održavanja manja od ukupne doze kladribina postignute na kraju perioda uvođenja (i);
A maintenance period lasting from 2 months to 4 months, wherein said Cladribine pharmaceutical formulation is to be administered and wherein the total dose of Cladribine reached at the end of the maintenance period (iii) is about 1.7 mg/kg; 
period održavanja, koji traje od 2 mjeseca do 4 mjeseca, kada navedenu kladribinsku farmaceutsku formulaciju treba primjenjivati i kada je ukupna doza kladribina postignuta na kraju perioda održavanja otprilike 1,7 mg/kg;
The Cladribine pharmaceutical formulation according to claim 3 for use or the use according to claim 4, wherein the formulation is to be orally administered following the sequential steps below: 
Kladribinska farmaceutska formulacija, namijenjena upotrebi u skladu s patentnim zahtjevom 3, ili upotreba u skladu s patentnim zahtjevom 4, naznačena time što formulaciju treba primijeniti oralno, prema sljedećim koracima, niže:
The Cladribine formulation for use or the use according to any of the preceding claims, wherein the pharmaceutical formulation is to be orally administered at a daily dose of 3 to 30 mg Cladribine. 
Kladribinska farmaceutska formulacija, namijenjena upotrebi, ili upotreba, u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što farmaceutsku formulaciju treba primijeniti oralno, u dnevnoj dozi od 3 do 30 mg kladribina.
The Cladribine formulation for use or the use according to any of the preceding claims, wherein the pharmaceutical formulation is to be orally administered at a daily dose of 10 mg Cladribine. 
Kladribinska farmaceutska formulacija, namijenjena upotrebi, ili upotreba, u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što farmaceutsku formulaciju treba primijeniti oralno, u dnevnoj dozi od 10 mg kladribina.
The Cladribine formulation for use or the use according to any of the preceding claims, wherein the pharmaceutical formulation is to be administered in combination with interferon-beta. 
Kladribinska farmaceutska formulacija, namijenjena upotrebi, ili upotreba, u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što farmaceutsku formulaciju treba primijeniti u kombinaciji s interferonom-β.
Device arranged for converting an AC input voltage to a DC output voltage, comprising a bridgeless boost converter; 
Uređaj namijenjen za pretvaranje izmjeničnog ulaznog napona u istosmjerni izlazni napon koji sadrži istosmjerni uzlazni pretvarač bez mosnog spoja:
The method of claim 7, wherein the immunosuppressant is selected from the group consisting of: glucocorticoid, including decortin, prednisol; azathioprine; cyclosporin A; tacrolimus; an anti-T lymphocyte globulin; an anti-CD3 antibody; muromonab; an anti-CD25 antibody; basiliximab; daclizumab; an anti-TNF-a antibody; infliximab; adalimumab; azathioprine; methotrexate; cyclosporin; sirolimus; everolimus; fingolimod; CELLCEPT® (mycophenolate mofetil); myfortic; and cyclophosphamide. 
Uporaba prema zahtjevu 2, naznačena time da je imunosupresijsko sredstvo odabrano iz skupine koja sadrži: glukokortikoid, uključujući dekortin, prednisol; azatioprin; ciklosporin A; mikofenolat mofetil; takrolimus; anti-T-limfocitni globulin, anti-CD3-antitijela, uključujući muromonab; anti-CD25-antitijela, uključujući baziliksimab i daklizumab; anti-TNF-a antitijela, uključujući infliksimab i adalimumab; azatioprin; metotreksat; ciklosporin; sirolimus; everolimus; fingolimod; CellCept; myfortic; te ciklofosfamid.
A composition suitable for control of diseases caused by phytopathogens comprising a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and (B) the compound fenpropimorph. 
Pripravak koji je pogodan za nadzor bolesti uzrokovanih fitopatogenim organizmima uključujući (A) spoj formule I [image] naznačen time da je R1 difluorometil ili trifluorometil, a X kloro, fluoro, ili bromo; i (B) spoj biksafen.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropimorph. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) biksafen.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropimorph. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) biksafen.
positioning the sample near the plume, such that the target material particles are deposited onto the surface of the sample; 
postavljanje uzorka blizu prašine, tako da se čestice ciljnog materijala nanose na površinu uzorka;
pulsing the laser or electron beam at a variable frequency. 
laser ili elektronska zraka pulsira promjenjivom frekvencijom.
A single chain protein multimer according to claim 1, wherein said linker consists of not more than 25 residues, less than 20 residues, less than 15 residues, or less than 10 residues. 
Jednolančani proteinski multimer prema zahtjevu 1, gdje se linker sastoji ne od više od 25 ostataka, manje od 20 ostataka, manje od 15 ostataka ili manje od 10 ostataka.
The co-crystal of claim 6, wherein the molar ratio of the compound having the structure and 4-hydroxybenzoic acid is about 1:1 and the molar ratio of the compound having the structure and acetonitrile is about 1: 0.14 and having at least two of the four X-ray powder diffraction peaks at about 7.684, 8.599, 9.605, 9.938 °2-Theta, each with a standard deviation of about +/- 0.3 °2-Theta, or having a DSC peak in its DSC thermogram at about 190.78 °C with a standard deviation of about +/- 5 °C. 
Sukristal u skladu s patentnim zahtjevom 6, naznačen time što molarni odnos između spoja sa strukturom [image] -hidroksibenzojeve kiseline iznosi otprilike 1:1, a molarni odnos između spoja sa strukturom [image] i acetonitrila iznosi otprilike 1:0,14 i ima najmanje dva od četiri signala difrakcije rendgenskih zraka na prahu na otprilike 7,684, 8,599, 9,605, 9,938 °2θ, od kojih svaki ima standardnu devijaciju od otprilike ± 0,3 °2θ, ili ima DSC signal u svom DSC termogramu na otprilike 190,78 °C, uz standardnu devijaciju od otprilike ± 5 °C.
The pharmaceutical composition of claim 8, further comprising a solvent, diluent, excipient, carrier, or solubilizing agent. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 8, naznačen time što dodatno sadrži otapalo, razrjeđivač, pomoćnu tvar, podlogu ili solubilizacijsko sredstvo.